# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (9...
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal InvestigatorSOUTH SAN FRANCISCO, Calif...
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of...
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does ...
https://www.fpds.gov/common/jsp/LaunchWebPage.jsp?command=execute&requestid=172813877&version=1.5
Aligos Therapeutics, Inc. (NASDAQ:ALGS, ", Aligos", )))), a clinical stage biopharmaceutical company focused on develop...